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ABSTRACT
Given that an influenza pandemic is likely within the
next few years, the World Health Organization has
recommended that policymakers take action to miti-
gate the consequences of such a pandemic. Because
of the increased risk of patients with cancer develop-
ing complications of influenza, policymakers in can-
cer care should immediately begin planning for
changes to resource allocation, clinical care, and the
consent process during a pandemic.
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1. INTRODUCTION
The World Health Organization (WHO) continues to
report new cases of human infection with the H5N1
avian influenza virus in Turkey and Southeast Asia.
The next influenza pandemic may not involve the
H5N1 strain, but given past epidemiologic patterns,
emergence of a new pandemic strain in the near fu-
ture is likely. The WHO has recommended that
policymakers take action to mitigate the consequences
of such an event 1. National, regional, and institutional
plans have been developed, but I am aware of none
that have addressed the unique needs of patients with
cancer.
Cancer patients are at increased risk of develop-
ing complications of influenza—specifically, bacte-
rial superinfection. Patients with cancer face all the
risks of the general population during a pandemic
and also have increased susceptibility to infection as
a result of their illness. For example, myeloma and
chronic lymphocytic leukemia are frequently associ-
ated with hypogammaglobulinemia; patients with
these diseases are therefore at risk for bacterial in-
fections. Increased susceptibility can also result from
the general debility caused by cancer. Additionally,
many cancer treatments increase the risk of compli-
cations of influenza through myelosuppression. These
unique risks mean that policymakers in cancer care
must urgently develop plans for changes in resource
allocation, clinical practice, and consent procedures
during an influenza pandemic.
2. DISCUSSION
2.1 Resource Allocation
It is estimated that 15%–35% of the general popula-
tion will become clinically ill during an influenza
pandemic 2. The percentage of health care workers
becoming ill could be higher than that of the general
population because of occupational exposure to the
virus. Preparedness plans therefore prioritize health
care workers for influenza vaccination and prophy-
laxis with antiviral medications. Despite these inter-
ventions, many health care workers will be
unavailable because of illness, fear of occupational
exposure to influenza, and illness within their own
families. With a reduced workforce, a reduction in
the number of cancer treatments delivered is an in-
evitability. Thus, rationing of oncology services will
be a reality.
We will have to make difficult decisions if the
workforce is reduced to 85% of normal. At 65% of
normal staffing, the decisions about who will receive
treatment will be agonizing. Clearly we will strive to
deliver potentially curative treatments. Not so obvi-
ous is how we will manage palliative therapies. We
may need to modify our concept of futility. For ex-
ample, should we give first- and second-line, but not
third-line, metastatic chemotherapy treatments? Pa-
tients unable to receive chemotherapy in such cir-
cumstances will still need expert supportive care;
palliative services will, however, be similarly strained
during a pandemic.
Issues of distributive justice will be front and
centre in the discussions of how we treat cancer pa-
tients during a pandemic. Perhaps we should give
preference to therapies that are less labour-intensive,
allowing us to treat more patients. For example, in
the adjuvant treatment of early breast cancer, the use
Influenza pandemic plan-
ning for cancer patients
P.M. Battershill MD
ORIGINAL ARTICLEINFLUENZA PANDEMIC PLANNING
CURRENT ONCOLOGY—VOLUME 13, NUMBER 4
120
of doxorubicin and cyclophosphamide (AC chemo-
therapy) for 4 cycles may allow us to treat more pa-
tients than would be possible if we used chemotherapy
regimens requiring 6 or 8 cycles. The AC chemo-
therapy may be slightly less effective in preventing
recurrence of the cancer in any one individual, but if
more people can be treated, the less effective treat-
ment may be justified.
Cancer care providers should assess their current
service capacity. Institutions currently functioning
near capacity will have greater difficulty providing
service when staff levels are decreased. Clearly, these
institutions will have greater challenges in resource
allocation.
2.2 Changes to Clinical Practice
In addition to standard measures of influenza pre-
vention—vaccination, careful attention to hand wash-
ing, and antiviral prophylaxis for people at high
risk—changes to standard oncology practice may
lessen the risks to cancer patients. Health care pro-
viders must always balance the risks of harm with
the potential for benefit when making treatment rec-
ommendations.
During a pandemic, the potential for benefit with
chemotherapy would be unchanged, but the risk of
harm would be increased to a degree that cannot be
readily quantified. Neutropenic patients who contract
influenza will be at significantly increased risk of
harm from bacterial superinfection. The use of he-
matopoietic colony–stimulating factors to prevent
chemotherapy-induced neutropenia is not routine with
most chemotherapy protocols 3. Greater use of such
factors to prevent neutropenia may be reasonable
during a pandemic, but would increase the cost of
treatment at a time when health care budgets will be
severely strained. Increased use of prophylactic anti-
biotics may prevent some superinfections 4, but at the
cost of increased bacterial resistance and antibiotic
related diarrhea.
Many patients will not be able to afford the extra
costs of the colony-stimulating factors and antibiot-
ics, raising the possibility that an influenza pandemic
would worsen the already existing health disparities
based on socioeconomic status. To ensure a just dis-
tribution of resources, planners should incorporate
an ethical component into their planning as suggested
in the report by the Joint Centre for Bioethics at the
University of Toronto 5. The suggested framework
identifies key ethical issues and provides a 15-point
guide for ethical influenza pandemic planning.
2.3 Consent Issues
Cancer patients need to know that myelosuppressive
treatment could carry greater risk during a pandemic.
In addition to the concerns mentioned earlier, the
usual supports for patients with febrile neutropenia
will be severely limited. Access to hospital beds will
be limited both by increased demand and by staff ill-
ness. In this circumstance, patients may well make
an informed choice for a potentially less efficacious
but less myelosuppressive treatment.
3. CONCLUSIONS
Policymakers in cancer care should immediately start
planning for cancer care delivery during an influenza
pandemic. However, no single plan will suffice for
all oncology practices. The needs of a pediatric ser-
vice will differ from the needs of a bone-marrow
transplant service.
We have the opportunity now to prepare for can-
cer care provision during a pandemic. To assure op-
timal treatment and fair distribution of resources, this
planning should start immediately.
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